Content about CAMBRIDGE

CAMBRIDGE, Mass. — The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

Genzyme, a division of French drug maker Sanofi, said the FDA accepted its application seeking approval for Lemtrada (alemtuzumab) for relapsing MS. The company expects the agency to decide whether to approve the drug in the second half of this year.

CAMBRIDGE, Mass. — Target should be feeling confident about its upcoming entry into Canada, as a recent survey from Kantar Retail and TNS Canada revealed that 75% of Canadians are aware of the retailer.

Furthermore, 43% of Canadian consumers said that they were likely to shop at Target Canada for grocery or health and beauty aids and 50% were likely to shop at Target Canada for general merchandise or apparel.

CAMBRIDGE, Mass. — Dollar General is the overall basket price leader, delivering a substantial savings to value shoppers, according to Kantar Retail's second annual opening price point survey. Walgreens, for the second year, had the most expensive total basket, driven by sharply higher edible and nonedible grocery baskets.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new drug for multiple sclerosis.

Sanofi subsidiary Genzyme announced that the FDA had approved Aubagio (teriflunomide) as a once-daily, oral treatment for patients with relapsing MS.

CAMBRIDGE, Mass. — While regulations meant to control the prices of drugs dispensed through physician offices for injured workers can keep costs down without limiting access, employers in many states may end up paying more than twice what they would have if the workers had gone to a pharmacy instead, according to a new study.

CAMBRIDGE, Mass. — An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.

Genzyme, a unit of French drug maker Sanofi, announced results from a phase-3 study of Aubagio (teriflunomide) in patients with relapsing forms of MS. According to the study, patients taking the drug in the 14-mg strength experienced a 36.3% reduction in annualized relapse rates and 31.5% reduction in the risk of sustained accumulation of disability over a 12-week period.

CAMBRIDGE, Mass. — Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.

Genzyme, owned by French drug maker Sanofi, will present results of 12 trials of the experimental drugs alemtuzumab and teriflunomide, including the phase-3 "CARE-MS II" trial, which compares alemtuzumab with Rebif (interferon beta-1a), made by Pfizer and Merck KGaA.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new means of administering a cancer drug made by Takeda, the drug maker said.

The FDA approved injection under the skin of Velcade (bortezomib) for multiple myeloma and mantle-cell lymphoma, also known as subcutaneous injection.

Takeda said the approval was based on results of a phase-3 trial conducted on 222 patients who had not received the drug before that showed subcutaneous injection worked as well as intravenous injection.

NEW YORK — Nielsen Holdings on Monday announced that Rick Kash has been appointed vice chair and will join CEO David Calhoun and vice chair Susan Whiting in the office of the CEO. Nielsen also named Mitchell Habib COO.

CAMBRIDGE, Mass. — Cambridge Consultants on Thursday released a report outlining how the health-and-wellness market may take shape as more consumer-friendly medical devices featuring the latest in technology reach the market.

“Disruption in this market will come from medical firms moving from 10-year product lifecycles and confronting the 18-month lifecycles of the consumer world, and from consumer companies adapting to the rigorous processes demanded by medical regulations,” stated Duncan Smith, head of product development at Cambridge Consultants.

CAMBRIDGE, Mass. — A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

Genzyme, acquired earlier this year by French drug maker Sanofi, announced results of the phase-3 "CARE-MS II" trial of Lemtrada (alemtuzumab), saying the drug "significantly reduced" worsening of disability and relapse in patients with MS, compared with Rebif (interferon beta-1a), made by Pfizer and German drug maker Merck KGaA, a separate company from U.S.-based Merck.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved changes to the labeling of a cancer drug made by Takeda Pharmaceuticals, the drug maker said.

Takeda and Millennium, the Japanese drug maker's cancer-drug subsidiary, announced Tuesday that the FDA approved a supplemental new drug application for the injectable multiple myeloma drug Velcade (bortezomib) that updates its label to include additional data from a clinical study showing that the drug extended patients' survival time.